![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLXNA3 |
Gene summary for PLXNA3 |
![]() |
Gene information | Species | Human | Gene symbol | PLXNA3 | Gene ID | 55558 |
Gene name | plexin A3 | |
Gene Alias | 6.3 | |
Cytomap | Xq28 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P51805 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55558 | PLXNA3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.01e-02 | 9.00e-02 | 0.0155 |
55558 | PLXNA3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.72e-07 | 3.44e-01 | -0.1808 |
55558 | PLXNA3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.16e-03 | 2.07e-01 | -0.0811 |
55558 | PLXNA3 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.41e-07 | 2.24e-01 | -0.1954 |
55558 | PLXNA3 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.49e-07 | 7.15e-01 | -0.2602 |
55558 | PLXNA3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.06e-04 | 2.33e-01 | -0.059 |
55558 | PLXNA3 | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.84e-02 | 2.52e-01 | -0.1706 |
55558 | PLXNA3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.12e-03 | 2.32e-01 | 0.3859 |
55558 | PLXNA3 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.20e-04 | 4.24e-01 | 0.2585 |
55558 | PLXNA3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.97e-06 | 2.63e-01 | 0.3005 |
55558 | PLXNA3 | HCC1_Meng | Human | Liver | HCC | 3.42e-10 | -1.76e-02 | 0.0246 |
55558 | PLXNA3 | HCC2_Meng | Human | Liver | HCC | 9.01e-12 | 1.13e-01 | 0.0107 |
55558 | PLXNA3 | S014 | Human | Liver | HCC | 4.90e-06 | 2.95e-01 | 0.2254 |
55558 | PLXNA3 | S015 | Human | Liver | HCC | 6.81e-07 | 3.93e-01 | 0.2375 |
55558 | PLXNA3 | S016 | Human | Liver | HCC | 7.44e-04 | 1.99e-01 | 0.2243 |
55558 | PLXNA3 | S027 | Human | Liver | HCC | 7.86e-22 | 1.47e+00 | 0.2446 |
55558 | PLXNA3 | S028 | Human | Liver | HCC | 9.54e-32 | 1.21e+00 | 0.2503 |
55558 | PLXNA3 | S029 | Human | Liver | HCC | 1.15e-27 | 1.24e+00 | 0.2581 |
55558 | PLXNA3 | C21 | Human | Oral cavity | OSCC | 1.97e-14 | 5.14e-01 | 0.2678 |
55558 | PLXNA3 | C30 | Human | Oral cavity | OSCC | 1.53e-11 | 6.16e-01 | 0.3055 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00459261 | Colorectum | SER | negative regulation of growth | 55/2897 | 249/18723 | 3.44e-03 | 2.92e-02 | 55 |
GO:00974851 | Colorectum | SER | neuron projection guidance | 51/2897 | 228/18723 | 3.61e-03 | 3.03e-02 | 51 |
GO:00615641 | Colorectum | SER | axon development | 94/2897 | 467/18723 | 3.78e-03 | 3.13e-02 | 94 |
GO:00074091 | Colorectum | SER | axonogenesis | 84/2897 | 418/18723 | 6.20e-03 | 4.49e-02 | 84 |
GO:00313451 | Colorectum | SER | negative regulation of cell projection organization | 42/2897 | 186/18723 | 6.51e-03 | 4.66e-02 | 42 |
GO:00325352 | Colorectum | MSS | regulation of cellular component size | 127/3467 | 383/18723 | 3.44e-12 | 5.79e-10 | 127 |
GO:00226042 | Colorectum | MSS | regulation of cell morphogenesis | 103/3467 | 309/18723 | 2.70e-10 | 2.56e-08 | 103 |
GO:00514952 | Colorectum | MSS | positive regulation of cytoskeleton organization | 78/3467 | 226/18723 | 6.86e-09 | 4.32e-07 | 78 |
GO:00430872 | Colorectum | MSS | regulation of GTPase activity | 101/3467 | 348/18723 | 1.00e-06 | 3.46e-05 | 101 |
GO:00083602 | Colorectum | MSS | regulation of cell shape | 52/3467 | 154/18723 | 4.40e-06 | 1.24e-04 | 52 |
GO:00313462 | Colorectum | MSS | positive regulation of cell projection organization | 96/3467 | 353/18723 | 3.44e-05 | 6.70e-04 | 96 |
GO:00109752 | Colorectum | MSS | regulation of neuron projection development | 115/3467 | 445/18723 | 6.91e-05 | 1.20e-03 | 115 |
GO:00160492 | Colorectum | MSS | cell growth | 123/3467 | 482/18723 | 7.15e-05 | 1.21e-03 | 123 |
GO:00107202 | Colorectum | MSS | positive regulation of cell development | 81/3467 | 298/18723 | 1.38e-04 | 2.06e-03 | 81 |
GO:00015582 | Colorectum | MSS | regulation of cell growth | 105/3467 | 414/18723 | 2.97e-04 | 3.90e-03 | 105 |
GO:00313452 | Colorectum | MSS | negative regulation of cell projection organization | 54/3467 | 186/18723 | 3.03e-04 | 3.96e-03 | 54 |
GO:00507671 | Colorectum | MSS | regulation of neurogenesis | 94/3467 | 364/18723 | 3.12e-04 | 4.06e-03 | 94 |
GO:00074092 | Colorectum | MSS | axonogenesis | 105/3467 | 418/18723 | 4.32e-04 | 5.23e-03 | 105 |
GO:00615642 | Colorectum | MSS | axon development | 115/3467 | 467/18723 | 5.33e-04 | 6.00e-03 | 115 |
GO:00486381 | Colorectum | MSS | regulation of developmental growth | 84/3467 | 330/18723 | 1.01e-03 | 1.01e-02 | 84 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
SEMA5A | PLXNA3 | SEMA5A_PLXNA3 | SEMA5 | CRC | AD |
SEMA5A | PLXNA3 | SEMA5A_PLXNA3 | SEMA5 | CRC | MSI-H |
SEMA5A | PLXNA3 | SEMA5A_PLXNA3 | SEMA5 | CRC | SER |
SEMA5A | PLXNA3 | SEMA5A_PLXNA3 | SEMA5 | HNSCC | Precancer |
SEMA4A | NRP1_PLXNA3 | SEMA4A_NRP1_PLXNA3 | SEMA4 | THCA | ADJ |
SEMA3C | NRP1_PLXNA3 | SEMA3C_NRP1_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3D | NRP1_PLXNA3 | SEMA3D_NRP1_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3C | NRP2_PLXNA3 | SEMA3C_NRP2_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3D | NRP2_PLXNA3 | SEMA3D_NRP2_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3F | NRP2_PLXNA3 | SEMA3F_NRP2_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA3G | NRP2_PLXNA3 | SEMA3G_NRP2_PLXNA3 | SEMA3 | THCA | ADJ |
SEMA4A | NRP1_PLXNA3 | SEMA4A_NRP1_PLXNA3 | SEMA4 | THCA | Cancer |
SEMA3A | NRP1_PLXNA3 | SEMA3A_NRP1_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA3C | NRP1_PLXNA3 | SEMA3C_NRP1_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA3D | NRP1_PLXNA3 | SEMA3D_NRP1_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA3C | NRP2_PLXNA3 | SEMA3C_NRP2_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA3D | NRP2_PLXNA3 | SEMA3D_NRP2_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA3F | NRP2_PLXNA3 | SEMA3F_NRP2_PLXNA3 | SEMA3 | THCA | Cancer |
SEMA5A | PLXNA3 | SEMA5A_PLXNA3 | SEMA5 | THCA | Cancer |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLXNA3 | SNV | Missense_Mutation | c.3275N>A | p.Arg1092Gln | p.R1092Q | P51805 | protein_coding | tolerated(0.63) | benign(0) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD | |
PLXNA3 | SNV | Missense_Mutation | c.4825G>C | p.Asp1609His | p.D1609H | P51805 | protein_coding | deleterious(0.01) | benign(0.077) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLXNA3 | SNV | Missense_Mutation | novel | c.3394N>G | p.Pro1132Ala | p.P1132A | P51805 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PLXNA3 | SNV | Missense_Mutation | novel | c.2191N>T | p.Arg731Trp | p.R731W | P51805 | protein_coding | deleterious(0.01) | probably_damaging(0.965) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
PLXNA3 | SNV | Missense_Mutation | c.706N>A | p.Val236Met | p.V236M | P51805 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
PLXNA3 | SNV | Missense_Mutation | novel | c.3953N>G | p.Lys1318Arg | p.K1318R | P51805 | protein_coding | tolerated(0.97) | benign(0.027) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLXNA3 | SNV | Missense_Mutation | novel | c.5208C>A | p.Phe1736Leu | p.F1736L | P51805 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLXNA3 | SNV | Missense_Mutation | novel | c.3763N>A | p.Arg1255Ser | p.R1255S | P51805 | protein_coding | tolerated(0.13) | probably_damaging(0.999) | TCGA-AR-A0TT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
PLXNA3 | SNV | Missense_Mutation | rs782020864 | c.763N>A | p.Glu255Lys | p.E255K | P51805 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-B6-A0I1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PLXNA3 | SNV | Missense_Mutation | c.5309N>T | p.Ser1770Leu | p.S1770L | P51805 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |